Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naporafenib +/- Spartalizumab in MAPK-altered Solid Tumors
NCT02607813Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jan 2016
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of naporafenib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), melanoma and 1 more (6 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events at 150 days and Incidence and nature of dose limiting toxicities at 56 days. Started Jan 2016; status: terminated.
02
Drugs
naporafenib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)melanomaovarian cancer
Beyond the preview
Go deeper on NCT02607813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607813.